Preclinical evaluation of MRG002, a novel HER2-targeting antibody-drug conjugate with potent antitumor activity against HER2-positive solid tumors.

ABSTRACT:

Background

ERBB2 is a proto-oncogene of multiple cancers including breast and gastric cancers with HER2 protein overexpression or gene amplification and has been proven clinically as a valid target for these cancers. HER2-targeting agents such as Herceptin®, Kadcyla® and ENHERTU® have been approved by the FDA for the treatment of breast cancer, but these drugs still face the challenge of acquired resistance and/or severe adverse reactions in clinical use. Therefore, there is significant unmet medical need for developing new agents that are more effective and safer for patients with advanced HER2-positive solid tumors including breast and gastric cancers.

Methods

We report here the making of MRG002, a novel HER2-targeted antibody drug conjugate (ADC), and preclinical characte

SUBMITTER: Li H 

PROVIDER: S-EPMC8441113 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature